🇺🇸 PF-04950615 in United States

28 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 28

Most-reported reactions

1. Acute Kidney Injury — 6 reports (21.43%)
2. Dyspnoea — 4 reports (14.29%)
3. Bradycardia — 3 reports (10.71%)
4. Dehydration — 3 reports (10.71%)
5. Angioedema — 2 reports (7.14%)
6. Cardiac Failure Congestive — 2 reports (7.14%)
7. Condition Aggravated — 2 reports (7.14%)
8. Fall — 2 reports (7.14%)
9. Haematoma — 2 reports (7.14%)
10. Muscle Spasms — 2 reports (7.14%)

Source database →

Frequently asked questions

Is PF-04950615 approved in United States?

PF-04950615 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PF-04950615 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.